Nephrocare Health Services Reports Strong Q1 FY27 Results, Driven by Revenue Growth and Operational Efficiency

Nephrocare Health Services Reports Strong Q1 FY27 Results, Driven by Revenue Growth and Operational Efficiency​

Nephrocare Health Services Limited, Asia's largest dialysis network under the brand 'NephroPlus', announced its unaudited Standalone and Consolidated financial results for the first quarter ended June 30, 2026. The company reported significant growth across key operational metrics and financial performance indicators.

Consolidated financial results show a robust top-line performance, with revenue reaching ₹281.8 crore in Q1FY27. This represents a 23.7% increase year-on-year (YoY) from the ₹227.8 crore reported in Q1FY26.

Adjusted EBITDA saw a strong rise of 30.7% YoY, reaching ₹65.1 crore, compared to ₹49.8 crore in Q1FY26. The Adjusted EBITDA Margin stood at 23.1% for Q1FY27, marking an improvement over the 21.9% margin seen in Q1FY26. Similarly, Adjusted PAT grew by 41.7% YoY to ₹36.8 crore, up from ₹26.0 crore in the corresponding period last year.

Operational performance metrics also reflected healthy growth for Nephrocare. Treatments increased by 13.3% YoY, reaching 10,31,084, up from 9,09,860 treatments in Q1FY26. Guest volumes grew at a rate of 13.0% YoY, rising to 38,262 guests from 33,868 in the previous quarter. Revenue Per Treatment (RPT) saw a notable improvement of 9.2% YoY, increasing to ₹2,733 from ₹2,503.

The consolidated performance data for Nephrocare Health Services Limited is presented below:


The company's operational highlights for Q1FY27 are summarized in the table below:


Commenting on the Q1FY27 results, Mr. Vikram Vuppala, Chairman & MD, noted that while many dialysis services globally are provided by pure play networks, only 21% of the market in India is served by such organizations today. He stated that NephroPlus, as a market leader in India, is positioned to gain disproportionately due to its focus on clinical quality and patient centricity as the industry transitions from unorganized to organized care delivery.

Mr. Rohit Singh, Group Chief Executive Officer, highlighted the strong financial performance, noting that revenue grew 23.7% year-on-year (YoY) to ₹282 crore, and EBITDA rose 30.7% YoY to ₹65 crore. He further mentioned crossing 10,30,000 treatments in the first quarter of this financial year. Mr. Singh also stated that NephroPlus's network now spans 550 operating clinics across five countries, including a milestone of 50 clinics in the Philippines.

Mr. Prashant Goenka, Chief Financial Officer, remarked that Q1 FY27 reflected the strength of the India platform, which operates profitably at some of the lowest price points globally. He emphasized that this efficiency, combined with high barriers to entry in dialysis care, allows the company confidence to scale into higher-price international markets while maintaining margin discipline.

Nephrocare Health Services Limited is Asia's largest dialysis network, owning and operating 550 dialysis centres across India, Nepal, the Philippines, Uzbekistan, and Saudi Arabia under the NephroPlus brand.

NEPHROPLUS Stock Price Movement​

Today, shares of Nephrocare Health Services Limited edged higher to settle at ₹712.3, gaining 2.77% in post-market trading. The stock moved within a solid intraday band, closing after hitting a high of ₹719.4 and reaching a low of ₹692.05 amid 237,830 shares traded.